摘要
目的探讨沙利度胺联合VAD方案治疗多发性骨髓瘤的可行性及安全性。方法将67例多发性骨髓瘤患者随机分为对照组32例和治疗组35例:对照组单用VAD方案化疗,治疗组在VAD方案基础上加用沙利度胺片,起始量100mg/d,每晚顿服或分早晚给药,根据患者耐受情况每2周增加100mg,最高剂量不超过600mg/d,维持此剂量6个月。观察两组临床疗效及不良反应。结果治疗组和对照组总有效率分别为82.9%和53.1%。两组总有效率比较,差异有统计学意义(P<0.05)。两组均无明显肝、肾功能损害及骨髓抑制,不良反应在对症处理后,症状均较快缓解。两组间不良反应比较,差异无统计学意义(P>0.05)。结论沙利度胺联合VAD方案治疗多发性骨髓瘤具有耐受性好、疗效肯定、不良反应少等优点,值得临床推广应用。
Objective To explore the feasibility and safety of Thalidomide and VAD scheme jointly treating multiple myeloma（MM）.Methods Total 67 MM patients were randomly divided into the control group with 32 cases and the treatment group 35 cases：the control group used solely VAD chemotherapy scheme,the treatment group used Thalidomide on the basis of VAD scheme,starting dose 100mg/d,every evening meal or taking medicine in the morning or evening,increased 100mg every 2 weeks according to tolerated situations of patients,the highest doses not more than 600mg/d,maintained the dose for 6 months.Observed clinical curative effect and adverse reaction of two groups.Results The total effective rates of treatment group and control group were respectively 82.9% and 53.1%.Total effectiveness of two groups compared,having significant differences （P〈0.05）.Both groups were not found significantly damage of liver and kidney,and bone marrow inhibit,symptomatic treatment in adverse reactions,symptoms alleviated rapidly.Adverse reactions of the two groups compared,there was no significant difference （P〉0.05）.Conclusion The treatment of Thalidomide combined with VAD scheme in multiple myeloma has advantages of superior tolerability,good curative effect,poor adverse reactions,etc,thus worth of clinically adoption and generalization.
出处
《医药论坛杂志》
2010年第3期1-2,6,共3页
Journal of Medical Forum
